Thursday 16 October, 2025
Objectives: Tuberculous meningitis (TBM) is the most fatal form of tuberculosis (TB) that is involves inflammation of the meninges. People…
Read morePoster: Drug/Disease Modelling - Infection
Population Pharmacokinetic Modeling of Linezolid in Plasma and Cerebrospinal Fluid in Adults with Tuberculous Meningitis (LASER-TBM Study)
Thursday 16 October, 2025
Objectives: Tuberculous meningitis (TBM) is associated with severe outcome, particularly among people living with HIV where mortality approaches 50% despite…
Read morePopulation pharmacokinetics of pyrazinamide in hospitalised TB patients with HIV versus TB outpatients
Thursday 16 October, 2025
Objectives: Hospitalised tuberculosis (TB) patients co-infected with human immunodeficiency virus (HIV) have high early mortality, more than 50% of deaths…
Read morePharmacokinetic Modelling of Rifampicin, Isoniazid, Pyrazinamide, and Linezolid in Central Nervous System: Insights from a Rabbit Model of Tuberculosis Meningitis
Thursday 16 October, 2025
Objectives: Tuberculosis meningitis (TBM) is the most devastating manifestation of M. tuberculosis infection causing high rates of mortality and disability…
Read moreUse of a semi-mechanistic PK-PD model to quantify the combination effect of polymyxin B and minocycline against polymyxin-resistant Acinetobacter baumannii
Thursday 16 October, 2025
Objectives: Acinetobacter baumannii is one of the most difficult to treat multi-drug resistant (MDR) pathogens responsible for opportunistic nosocomial infections…
Read moreExposure-QTc modelling of Bedaquline, Clofazimine and Pretomanid in TB patients.
Thursday 16 October, 2025
Objectives: The occurrence of drug resistance (DR) to tuberculosis (TB) medications poses critical challenges to global efforts to manage TB….
Read moreClofazimine population pharmacokinetics in South African patients with drug resistant tuberculosis
Thursday 16 October, 2025
Objectives: Clofazimine is a key component of the short regimen for drug-resistant tuberculosis (TB) but there is currently no evidence…
Read morePopulation Pharmacokinetic/Pharmacodynamic Modelling of Clofazimine Effects on QTcF in South African tuberculosis patients
Thursday 16 October, 2025
Objectives: Clofazimine is recommended by the World Health Organization and the American Thoracic Society for patients with rifampicin-resistant tuberculosis (TB). Clofazimine…
Read moreColistin to overcome resistance to ciprofloxacin – Quantifying combined effects of colistin and ciprofloxacin against four E. coli strains with different ciprofloxacin susceptibility in an in silico PKPD model
Thursday 16 October, 2025
Introduction/Objectives: Resistance to ciprofloxacin (CIP) is common for E. coli worldwide and colistin (CST) may overcome and/or prevent emergence of…
Read moreQuantification and prediction of the combined effect of minocycline and polymyxin B on multidrug-resistant Klebsiella pneumoniae
Thursday 16 October, 2025
Objectives: The increasing prevalence of refractory multidrug resistant bacteria calls for new approaches to suggest effective antibiotic combination therapies. The combined…
Read more